-
Presentation of Cevira® Phase 2b Results05 Dec 2012 -
PHOTOCURE ANNOUNCES POSITIVE RESULTS OF CEVIRA® STUDYRESULTS DEMONSTRATE SIGNIFICANT EFFICACY IN TREATMENT OF LESIONS AND ONCOGENIC HUMAN PAPILLOMA VIRUS IN PATIENTS WITH PRECANCEROUS LESIONS OF THE CERVIX05 Dec 2012
-
Results third quarter and first nine months 2012Oslo, Norway, 26 October 2012: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the third quarter and the first nine months 2012, for the period ended 30 September 2012.26 Oct 2012
-
Presentation of the third quarter 2012 report23 Oct 2012
-
Photocure to Exit Allumera BusinessOslo, Norway, 1 October 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that it has made the strategic decision to exit its Allumera® cosmetic dermatology business in the US.01 Oct 2012
-
Results second quarter and first half 2012Oslo, Norway, 24 August 2012: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the second quarter and the first half year 2012, for the period ended 30 June 2012.24 Aug 2012
-
Photocure ASA – Presents second quarter and first half year 2012 report on Friday August 24th.Kjetil Hestdal, President & CEO will present the report at 15:00 CET22 Aug 2012
-
Interview: Simplifying Existing Procedure Eases Market Penetration for PhotocurePresident and CEO Kjetil Hestdal discusses the company's photodynamic technology harnessed in Hexvix® and Allumera®. Hexvix®, branded as Cysview® in the U.S., aids in cystoscopy procedures for bladder cancer.06 Jul 2012
-
Photocure strengthens the management teamAnnounces appointment of Chief Finance Officer05 Jul 2012
-
Final transition milestone for Hexvix® achievedA total of EUR 5 million in manufacturing milestones achieved to date18 Jun 2012
-
Presentation and webcast of Visonac® phase 2b results 31 May 15.00 CETAccess to webcast and presentation via this link: http://webtv.hegnar.no/webcast.php?id=6554231 May 2012
-
Photocure announces positive results of phase 2b study evaluating Visonac® in acneResults demonstrate a significant reduction in inflammatory lesions and a significant improvement in overall acne severity.31 May 2012
-
Data presented shows that Hexvix® cystoscopy significantly improves time to recurrence of bladder cancerPhotocure to present data on impact of Hexvix®/Cysview® on long term recurrence rates at American Urological Association annual meeting, Atlanta, GA, USA. The results indicates that Hexvix cystoscopy significantly improves time to recurrence of bladder cancer.22 May 2012
-
Enhanced market access to Cysview® in the US marketPhotocure announces FDA approval of upgraded Karl Storz blue light cystoscope for use with Cysview. This will significantly enhance the market access to Cysview in the US market.07 May 2012
